Swiss National Bank Has $1.09 Million Holdings in Bicara Therapeutics Inc. $BCAX

Swiss National Bank lifted its holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX) by 70.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,000 shares of the company’s stock after purchasing an additional 22,700 shares during the quarter. Swiss National Bank owned 0.08% of Bicara Therapeutics worth $1,094,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BCAX. Deutsche Bank AG grew its position in Bicara Therapeutics by 0.9% in the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after purchasing an additional 1,171 shares in the last quarter. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares in the last quarter. Mariner LLC lifted its position in Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after buying an additional 1,902 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after buying an additional 1,962 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth about $45,000.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $27.10 on Friday. Bicara Therapeutics Inc. has a 52 week low of $9.57 and a 52 week high of $30.99. The stock has a market capitalization of $1.78 billion, a P/E ratio of -9.75 and a beta of -0.81. The stock has a 50-day simple moving average of $25.19 and a 200 day simple moving average of $21.20.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Research analysts forecast that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current year.

Insider Transactions at Bicara Therapeutics

In related news, CFO Ivan Hyep sold 28,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $28.85, for a total transaction of $807,800.00. Following the transaction, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. The trade was a 17.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total value of $817,641.72. Following the transaction, the chief operating officer directly owned 182,177 shares in the company, valued at $5,279,489.46. The trade was a 13.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 88,450 shares of company stock worth $2,366,675. 13.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on BCAX shares. The Goldman Sachs Group lifted their target price on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Guggenheim began coverage on Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price target for the company. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. Finally, Morgan Stanley boosted their price target on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $30.27.

Bicara Therapeutics Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.